TY  -  
T1  - Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia 
SN  -  /  
UR  - http://hdl.handle.net/10138/342170 
T3  -  
A1  - Malani, Disha; Kumar, Ashwini; Brück, Oscar; Kontro, Mika; Yadav, Bhagwan; Hellesoy, Monica; Kuusanmäki, Heikki; Dufva, Olli; Kankainen, Matti; Eldfors, Samuli; Potdar, Swapnil; Saarela, Jani; Turunen, Laura; Parsons, Alun; Västrik, Imre; Kivinen, Katja; Saarela, Janna; Räty, Riikka; Lehto, Minna; Wolf, Maija; Gjertsen, Bjorn Tore; Mustjoki, Satu; Aittokallio, Tero; Wennerberg, Krister; Heckman, Caroline A.; Kallioniemi, Olli; Porkka, Kimmo 
A2  -  
PB  -  
Y1  - 2022 
LA  - eng 
AB  - We generated ex vivo drug-response and multiomics profi ling data for a prospective series of 252 samples from 186 patients with acute myeloid leukemia (AML). A functional precision medicine tumor board (FPMTB) integrated clinical, molecular, and functional data for application in clinical treatment decisions. Actionable drugs were found for 97% of patients with AML, and the recommendations were clinically implemented in 37 relapsed or refractory patients. We report a 59% objective response rate... 
VO  -  
IS  -  
SP  -  
OP  -  
KW  - PATIENT SAMPLES; CHEMOTHERAPY; VENETOCLAX; INHIBITORS; ENASIDENIB; ONCOLOGY; EFFICACY; 3122 Cancers 
N1  -   
PP  -  
ER  -